xalkori
pfizer europe ma eeig - crizotinib - carcinom, ikke-småcellet lunge - antineoplastiske midler - xalkori as monotherapy is indicated for:the first‑line treatment of adults with anaplastic lymphoma kinase (alk)‑positive advanced non‑small cell lung cancer (nsclc)the treatment of adults with previously treated anaplastic lymphoma kinase (alk)‑positive advanced non‑small cell lung cancer (nsclc)the treatment of adults with ros1‑positive advanced non‑small cell lung cancer (nsclc)the treatment of paediatric patients (age ≥6 to.
omeprazol "orion" 10 mg enterokapsler, hårde
orion corporation - omeprazol - enterokapsler, hårde - 10 mg
reopro 2 mg/ml injektions-/infusionsvæske, opløsning
orifarm a/s - abciximab - injektions-/infusionsvæske, opløsning - 2 mg/ml
artiss vævsklæber
baxter a/s - aprotinin, calciumchloriddihydrat, human fibrinogen, thrombin, humant - vævsklæber
tisseel vævsklæber
baxter a/s - aprotinin, calciumchloriddihydrat, fibrinogen, koagulationsfaktor xiii, humant, thrombin, humant - vævsklæber
durogesic 100 mikrogram/time depotplastre
janssen-cilag a/s - fentanyl - depotplastre - 100 mikrogram/time
durogesic 12 mikrogram/time depotplastre
janssen-cilag a/s - fentanyl - depotplastre - 12 mikrogram/time
durogesic 25 mikrogram/time depotplastre
janssen-cilag a/s - fentanyl - depotplastre - 25 mikrogram/time
durogesic 50 mikrogram/time depotplastre
janssen-cilag a/s - fentanyl - depotplastre - 50 mikrogram/time
durogesic 75 mikrogram/time depotplastre
janssen-cilag a/s - fentanyl - depotplastre - 75 mikrogram/time